Keio Innovation Initiative contributed to a $20m round that increased the total funding for medical access app developer CureApp, partially based on Keio University research, to nearly $39m.
Japan-based medical booking app developer CureApp received ¥2.2bn ($20.4m) in funding from investors including Keio Innovation Initiative (KII), the venture fund of Keio University, today.
The round also featured diversified trading group Itochu’s corporate venturing unit Itochu Technology Ventures (ITV), insurance provider Dai-ichi Life and property developer Mori Trust.
Mizuho Capital, the venture capital arm of financial services group Mizuho Bank, as well as holding companies Koshidaka and Intage, VC firm Iwagin Jigyo Souzou Capital filled out the round.
CureApp has built an app that allows patients to access tailored therapeutic intervention outside of normal hospital hours. It also works with corporate clients to promote their employees’ physical and mental wellness.
The funding will be used to address struggles faced by Japan’s healthcare system, including financial challenges and a shortage of doctors. The company also plans to leverage the resources of its corporate investors to improve…
